Next-generation/high throughput sequencing studies on resistant/refractory recurrent ovarian cancer tissue samples showed loss of hypermethylation I promotor region of BRCA gene and also reversions in germline BRCA1/2 mutation, which may led to higher genome stability [78]. This evidence concerns the gene BRCA1 and ovarian cancer.